It is proposed that drugs targeting the heme pathway could be a therapeutic option in LUAD patients with dysregulation of KEAP-NRF2 pathway, often mutated in K-Ras mutant NSCLC [179]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.